Reagenzien und Instrumente für die Immunologie Zellbiologie und Molekularbiologie
 
> Ince Primary T-Cell Leukemia Media (Ince TLMI) (Liquid)

Ince Primary T-Cell Leukemia Media (Ince TLMI) (Liquid)

Drucken Drucken
Melden Sie sich an

Katalog-Nummer 506392-500ml

Size : 500ml

Marke : US Biological

Contact local distributor :


Telefonnummer : +1 850 650 7790

506392 Rabbit Anti-Ince Primary T-Cell Leukemia Media (Ince TLMI) (Liquid)

Clone Type
Polyclonal
Shipping Temp
Blue Ice
Storage Temp
4°C Do Not Freeze

Primary T-Cell Leukemia Media (Ince)||Tan A. Ince, MD, PhD - Fighting Cancer by Keeping Cancer Cells Alive ...|https://www.scientia.global/tan-ince-md-phd-fighting-cancer-keeping-cancer-cells-alive/||Feb 12, 2017 - Professor Ince was a visiting clinical scientist at the Massachusetts Institute of Technology from 2000 to 2007, where he developed a new cell culture nutrient medium that is now widely used to grow human breast and ovary cells.||Appearance:|Red, clear, complete||FOMI Bullet 1 Included (506392B, |Colorless): |Supplied as a liquid. Vortex, spin down and add whole vial to 506388. ||Storage (506392B):|Liquid is stable at 4°C.||FOMI Bullet 3 Included (506392D, |Pink): |Supplied as a liquid. Thaw, vortex, spin down and add whole vial to 506388.||Storage (506392D):|Liquid is stable at -20°C.||Storage and Stability (506392)|(w/o supplements):|Store at 4°C. Do not freeze. Light sensitive, store in the dark. Stable for 6 months w/o supplements.||Storage and Stability (506392) |(w/ supplements):|Complete media with supplements is stable for 6 weeks at 4°C. Do Not Freeze. Light sensitive, store in the dark.||Born Date:|As Reported ||Country of Origin|United States||Licensed by TumorGenesisTM. Manufactured for research use by US Biological.

Applications
Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological. Toxicity and Hazards: All products should be handled by qualified personnel only, trained in laboratory procedures.
References
1. Tan A. Ince, MD, PhD - Fighting Cancer by Keeping Cancer Cells Alive ...|https://www.scientia.global/tan-ince-md-phd-fighting-cancer-keeping-cancer-cells-alive/|2. AE Witt, CW Lee, TI Lee, DI Azzam, B Wang, C Caslini, F Petrocca, J Grosso, M Jones, EB Cohick, AB Gropper, C Wahlestedt, AL Richardson, R Shiekhattar, RA Young and TA Ince, Identification of a cancer stem cell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer, Oncogene, 2016. DOI: 10.1038/ onc.2016.337|3. A Thakkar, B Wang, M Picon-Ruiz, P Buchwald and TA Ince, Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer, Breast Cancer Res. Treat., 2016, 157, 77–90.|4. TA Ince, AD Sousa, MA Jones, JC Harrell, ES Agoston, M Krohn, LM Selfors, W Liu, K Chen, M Yong, P Buchwald, B Wang, KS Hale, E Cohick, P Sergent, A Witt, Z Kozhekbaeva, S Gao, AT Agoston, MA Merritt, R Foster, BR Rueda, CP Crum, JS Brugge, GB Mills, Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours, Nat. Commun., 2015, 6, 7419.|5. S Santagata, A Thakkar, A Ergonul, B Wang, T Woo, R Hu, JC Harrell, G McNamara, M Schwede, AC Culhane, D Kindelberger, S Rodig, A Richardson, SJ Schnitt, RM Tamimi and TA Ince, Taxonomy of breast cancer based on normal cell phenotype predicts outcome, J. Clin. Invest., 2014, 124, 859–870.